Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body.
Causes, incidence, and risk factors
GVHD may occur after a bone marrow or stem cell transplant in which someone receives bone marrow tissue or cells from a donor (called an allogeneic transplant). The new, transplanted cells regard the recipient's body as foreign. When this happens, the newly transplanted cells attack the recipient's body.
GVHD does not occur when someone receives his or her own cells during a transplant (called an autologous transplant).
Before a transplant, tissue and cells from possible donors are checked to see how closely they match the person having the transplant. GVHD is less likely to occur, or symptoms will be milder, when the match is close. The chance of GVHD is:
Very low when a person receives bone marrow or cells from an identical twin
Around 30 - 40% when the donor and recipient are related
Around 60 - 80% when the donor and recipient are not related
There are two types of GVHD: acute and chronic. Symptoms in both acute and chronic GVHD range from mild to severe.
Acute GVHD usually happens within the first 3 months after a transplant. Common acute symptoms include:
Dry mouth, white patches inside the mouth, and sensitivity to spicy foods
Fatigue, muscle weakness, and chronic pain
Skin rash with raised, discolored areas, as well as skin tightening or thickening
Shortness of breath
Signs and tests
Several lab and imaging tests can be done to diagnose and monitor problems caused by GVHD.
A biopsy of the skin, mucus membranes in the mouth, or other parts of the body may help confirm the diagnosis.
After a transplant, the recipient usually takes drugs that supress the immune system. This helps reduce the chances (or severity) of GVHD.
A number of medicines and other treatments are often started after the transplant. You will continue taking the medicines until your health care provider thinks the risk of GVHD is low. Many of these medicines have side effects, including kidney and liver damage. You will have tests to watch for these problems on a regular basis.
Treatment of chronic GVHD includes prednisone (a steroid), or the same drugs that suppress the immune system.
How well a person does depends on the severity of GVHD. The outlook is better for patients who receive closely matched bone marrow tissue and cells.
Some cases of GVHD can damage the liver, lungs, digestive tract, or other body organs. Patients may also be at risk for severe infections.
However many cases, acute or chronic, can be treated successfully.
Successful treatment of GVHD does not guarantee that the transplant itself will succeed in treating the original disease.
Calling your health care provider
If you have had a bone marrow or stem cell transplant, call your health care provider right away if you develop any symptoms of GVHD or other unusual symptoms.
Sykes M. Transplantation immunology. In Goldman L, Schafer AI, eds. Cecil Medicine. 24th ed. Philadelphia, Pa: Saunders Elsevier; 2011:chap 48.
David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M. Health Solutions, Ebix, Inc.